Phoundry Pharmaceuticals acquired by Boston firm

Boston-based Intarcia Therapeutics Inc. has acquired Phoundry Pharmaceuticals Inc., founded this year after six years of work as part of GlaxoSmithKline’s enteroendocrine discovery performance unit. Financial details were not disclosed. Both companies work with peptide therapies, with Intarcia focusing on obesity and diabetes. Kurt Graves, chair, president and CEO of Intarcia says both companies share a common vision that combination therapies of optimized peptides have the potential to mimic and extend the metabolic benefits and weight loss potential associated with bariatric surgery.” The therapies would be delivered via Intarcia’s mini-pumps once or twice yearly. Graves said Intarcia will “leave...

Read More